雄黄纳米颗粒与三氧化二砷化合物在体外和体内诱导抗多发性骨髓瘤活性
本研究比较雄黄纳米颗粒(NREA)与三氧化二砷(ATO)对多发性骨髓瘤(MM)细胞系及患者细胞的细胞毒性,两者在体内均显示抗MM活性并显著减少肿瘤负荷;NREA的抗MM活性较ATO更强,且NREA可显著降低MM干细胞样侧群比例和克隆形成能力。
要点
- NREA与ATO在体外和体内均显示抗MM活性,显著减少肿瘤负荷。
- NREA诱导G2/M期阻滞并调节cyclin B1、p53、p21、Puma和Wee-1。
- NREA可显著降低MM干细胞样侧群比例和克隆形成能力,ATO无此作用。
核心结论
- NREA的抗MM活性较ATO更强,为改善MM患者结局的临床试验提供了临床前框架。
研究设计与样本
- 本研究为体外和体内研究,比较雄黄纳米颗粒(NREA)与三氧化二砷(ATO)对多发性骨髓瘤细胞系及患者细胞的细胞毒性。
主要发现
- NREA和ATO在体内均显示抗MM活性,显著减少肿瘤负荷。
- NREA和ATO的抗MM活性与凋亡相关,表现为DNA片段化、线粒体膜电位耗竭、caspases和抗凋亡蛋白剪切。
- NREA诱导G2/M期细胞周期阻滞并调节cyclin B1、p53(TP53)、p21(CDKN1A)、Puma(BBC3)和Wee-1(WEE1)。
- NREA调节MM发病机制中的关键调控分子,包括JNK激活、c-Myc(MYC)、BRD4和组蛋白。
- NREA而非ATO可显著降低MM干细胞样侧群的比例和克隆形成能力,即使在骨髓基质细胞存在的情况下亦然。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM), a B cell malignancy characterized by clonal proliferation of plasma cells in the bone marrow, remains incurable despite the use of novel and conventional therapies. In this study, we demonstrated MM cell cytotoxicity triggered by realgar (REA; As4 S4 ) nanoparticles (NREA) versus Arsenic trioxide (ATO) against MM cell lines and patient cells. Both NREA and ATO showed in vivo anti-MM activity, resulting in significantly decreased tumour burden. The anti-MM activity of NREA and ATO is associated with apoptosis, evidenced by DNA fragmentation, depletion of mitochondrial membrane potential, cleavage of caspases and anti-apoptotic proteins. NREA induced G2 /M cell cycle arrest and modulation of cyclin B1, p53 (TP53), p21 (CDKN1A), Puma (BBC3) and Wee-1 (WEE1). Moreover, NREA induced modulation of key regulatory molecules in MM pathogenesis including JNK activation, c-Myc (MYC), BRD4, and histones. Importantly, NREA, but not ATO, significantly depleted the proportion and clonogenicity of the MM stem-like side population, even in the context of the bone marrow stromal cells. Finally, our study showed that both NREA and ATO triggered synergistic anti-MM activity when combined with lenalidomide or melphalan. Taken together, the anti-MM activity of NREA was more potent compared to ATO, providing the preclinical framework for clinical trials to improve patient outcome in MM.
引用
- Cholujova D, Bujnakova Z, Dutkova E, et al. Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma. Br J Haematol. 2017. PMID: 29048129. doi:10.1111/bjh.14974
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。